论文部分内容阅读
目的观察莫沙必利对糖尿病胃肠功能紊乱的临床疗效。方法 41例符合WHO诊断标准的2型糖尿病并胃肠功能紊乱患者,随机分为治疗组和对照组,在控制血糖的基础治疗上,分别给予莫沙必利(治疗组)和维生素B1(对照组)口服。结果治疗组胃肠功能紊乱症状明显改善,总有效率95.2%,且两组有显著统计学差异(P<0.001)。结论促胃肠动力药莫沙必利能有效治疗糖尿病胃肠功能紊乱。
Objective To observe the clinical efficacy of mosapride on diabetic gastrointestinal disorders. Methods Forty-one patients with type 2 diabetes mellitus and gastrointestinal dysfunction complying with the WHO diagnostic criteria were randomly divided into treatment group and control group. Mosapride (treatment group) and vitamin B1 (control group) Group) orally. Results The symptoms of gastrointestinal disorders in the treatment group were significantly improved with a total effective rate of 95.2%. There was a significant difference between the two groups (P <0.001). Conclusions Gastrointestinal motility drug mosapride can effectively treat diabetic gastrointestinal disorders.